Advertisement

Early Identification and Treatment of Patients with Acute Coronary Syndromes

  • Costas T. Lambrew
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Mortality from acute myocardial infarction (AMI) has been dramatically reduced through successful myocardial reperfusion strategies with thrombolytics or primary percutaneous transluminal coronary angioplasty. The 6.3% mortality in the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) I Trial is approximately half the mortality for patients with AMI reported in the immediate prethrombolytic era (1). Reduced mortality is directly related to early reperfusion of the infarct-related artery and myocardial salvage; clear evidence from both the original animal work and extensive clinical trials with all agents supports this time-dependent relationship (2). The time-benefit curve is very steep, with maximum benefit accruing to those patients who are reperfused within the first 1–2 h after symptomatic occlusion. Analysis of clinical trials provides evidence that equates 1 hour of delay in reperfusion to an increase in absolute mortality by approximately 1%, or 10 lives per thousand; this is a linear relationship in the first 4–6 h following symptom onset (2, 3) (Fig. 1). Therefore, it is imperative that time be considered as much of an adjunct to the treatment of patients with AMI, as proposed by Cannon, as drugs that have been shown to have efficacy in reducing mortality (4).

Keywords

Acute Myocardial Infarction Acute Myocardial Infarction Emergency Medical Service Reperfusion Therapy Continuous Quality Improvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.Google Scholar
  2. 2.
    Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Left ventricular dysfunction and early cardiac events as a function of time to treatment with tPA: a report from TIMI II. Circulation 1991; 84: II - 230 (abstract).Google Scholar
  3. 3.
    Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996; 27: 1646–1655.PubMedCrossRefGoogle Scholar
  4. 4.
    Cannon CP, Antman FM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994; 1: 27–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Proceedings of the National Heart, Lung, and Blood Institute Symposium on Rapid Identification and Treatment of Acute Myocardial Infarction. U.S. Department of Health and Human Services. U.S. Government Printing Office, Washington, DC, 1991.Google Scholar
  6. 6.
    Lambrew CT, Smith MS. National Heart Attack Alert Coordinating Committee, 60 Minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994; 23; 311–329.CrossRefGoogle Scholar
  7. 7.
    Gruppo Italiano per to Studio della Streptochinasi nell’ Infarcto Miocatdico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401.Google Scholar
  8. 8.
    The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–627.Google Scholar
  9. 9.
    Dracup K, Alonzo AA, Atkins JM, Bennett NM, Braslow A, et al. for the Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. The physician’s role in minimizing delay in patients at high risk for acute myocardial infarction; recommendations from the National Heart Attack Alert Program. Ann Intern Med 1997; 126: 645–651.PubMedCrossRefGoogle Scholar
  10. 10.
    Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103 2114.Google Scholar
  11. 11.
    Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between onset of chest pain and seeking medical care: the effect of public education. Ann Emerg Med 1989; 18: 724–731.Google Scholar
  12. 12.
    Kereiakes DJ, Gibler WB, Martin LH, Peiper KS, Anderson LC and the Cincinnati Heart Project Study Group. Relative importance of emergency medical system transport and the prehospital electrocardiogram on reducing hospital time delay to therapy for acute myocardial infarction. Am Heart J 1992; 123: 833–840.CrossRefGoogle Scholar
  13. 13.
    Canto JC, Rogers WJ, Bowlby LJ, French WJ, Pearce DJ, Weaver WD. For the National Registry of Myocardial Infarction 2 Investigators. The prehospital electrocardiogram in acute myocardial infarction: is its full potential being realized? J Am Coll Cardiol 1997; 29: 498–505.PubMedCrossRefGoogle Scholar
  14. 14.
    Lambrew CT, Weaver WD, Rogers WJ, Bowlby LJ, Rubison RM, French WJ for the Participants in the National Registry of Myocardial Infarction. Hospital protocols and policies that may delay early identification and thrombolytic therapy of acute myocardial infarction patients. J Thromb Thrombolysis 1996; 3: 301–306.PubMedGoogle Scholar
  15. 15.
    Lambrew CT, Bowlby LJ, Rogers WJ, Chandra NC, Weaver WD. Factors influencing the time to thrombolysis in acute myocardial infarction. Arch Intern Med 1997; 157: 2477–2582.CrossRefGoogle Scholar
  16. 16.
    Lambrew CT. Emergency department triage of patients with non-traumatic chest pain. Acc Curr J Rev 1995; 4: 61–62.CrossRefGoogle Scholar
  17. 17.
    Maynard C, Weaver WD, Lambrew C, Bowlby LJ, Rogers WJ, Rubison RM for the Participants in the National Registry of Myocardial Infarction. Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator. Am J Cardiol 1995; 76: 548–552.PubMedCrossRefGoogle Scholar
  18. 18.
    Cannon CP, Lambrew CT, Tiefenbrunn AJ, French WJ, Gore JM, Weaver WD, et al., for the NRMI-2 Investigators. Influence of door-to-balloon time on mortality in primary angioplasty. Results in 3,648 patients in the Second National Registry of Myocardial Infarction (NRMI 2). J Am Coll Cardiol 1996; 27 (Suppl A): 61A.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Costas T. Lambrew

There are no affiliations available

Personalised recommendations